Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

NCT07806149 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT07806149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07806149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 19, 2026
Completion date
March 1, 2030
Enrollment
200 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hypertrophic cardiomyopathy, left ventricular outflow obstruction, systolic anterior motion